Targeted Oncology

译名:靶向肿瘤学

SCIEJCR Q1

5-10

2026

影响因子区间

平台估算

投稿周期

5%

2025

中国作者发文占比

3150 CHF

费用说明

收费

期刊简介:Targeted Oncology addresses physicians and scientists committed to oncology and cancer research by providing a programme of articles on molecularly targeted pharmacotherapy in oncology. The journal includes:Original Research Articles on all aspects of molecularly targeted agents for the treatment of cancer, including immune checkpoint inhibitors and related approaches.Comprehensive narrative Review Articles and shorter Leading Articles discussing relevant clinically established as well as emerging agents and pathways.Current Opinion articles that place interesting areas in perspective.Therapy in Practice articles that provide a guide to the optimum management of a condition and highlight practical, clinically relevant considerations and recommendations.Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement.Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

【译文】针对肿瘤学的研究人员和医生,通过提供关于肿瘤学分子靶向药物治疗的文章系列,该期刊涵盖了包括免疫检查点抑制剂在内的所有分子靶向治疗药物的研究,以及相关的治疗方法和途径。

出版社
Adis, Springer Healthcare
语言
English
学科
医学
ISSN
1776-2596
eISSN
1776-260X
出版频率
季刊
创刊年份
2006
投稿网址
https://www.editorialmanager.com/targ
最近更新
2026-04-02 18:16:40
Targeted Oncology

指标当前值近三年趋势
JCR分区Q1
暂无
影响因子区间5-10
暂无